Financial Performance - HEPLISAV-B net product revenue reached $90 million in Q3'25, a 13% year-over-year increase compared to $79 million in Q3'24[5, 81] - The company anticipates HEPLISAV-B net revenue to be between $315 million and $325 million for the full year 2025[78] - Adjusted EBITDA for FY 2025 is expected to be at least $80 million, revised up from the previous guidance of at least $75 million[9, 79, 85] - Cash, cash equivalents, and marketable securities totaled approximately $648 million as of September 30, 2025[7, 83] - Total revenues for Q3'25 were $949 million, an 18% increase from $806 million in Q3'24[77] Market Position and Strategy - HEPLISAV-B's total U S market share reached 46% at the end of Q3'25, compared to 44% in Q3'24[5, 81] - The U S adult Hepatitis B vaccine market is projected to peak at over $900 million by 2030, with HEPLISAV-B expected to achieve at least 60% of the total U S market share[5, 25] - The company is focused on maximizing HEPLISAV-B's commercial potential, advancing its diversified vaccine pipeline, and continuing a balanced capital allocation strategy[12] Pipeline Development - The company's plague vaccine program received approximately $14 million in additional funding from the U S DoD, bringing the total funding to approximately $44 million through the first half of 2027[11, 87] - Dynavax entered into an exclusive license agreement for Vaxart's oral COVID-19 vaccine candidate, involving a $25 million upfront payment and a $5 million equity investment[68] - The global shingles vaccine market size was approximately $42 billion in 2024[33]

Financial Performance - Revenue for Q3 2025 reached $125 million, a 2.7% increase compared to $122 million in Q3 2024[9, 22] - Gross margin was 38.7% in Q3 2025, compared to 42.3% in Q3 2024[9, 24] - Adjusted EBITDA was $13.8 million, representing an 11.0% margin, compared to $12 million and 10.1% margin in Q3 2024[9, 24] - Adjusted net loss was $7 million in Q3 2025, compared to $4 million in Q3 2024[24] Revenue Mix & Growth Pillars - Grills accounted for 61% of revenue, consumables 19%, and accessories 20%[10, 11] - Consumables revenue increased by approximately 12% in Q3 2025[13] - Accessories line realized double-digit growth[13] Project Gravity - Project Gravity aims for $50 million in annualized run-rate savings once fully implemented by the end of 2026[6, 15, 16] - Phase 1 includes a reduction in force and MEATER centralization, yielding approximately $30 million in savings[16] - Phase 2 includes channel optimization and other productivity measures, yielding approximately $20 million in savings[6, 16] Tariff Mitigation & Balance Sheet - The company is diversifying production outside of China to mitigate tariff risks, expecting a meaningful production shift by the end of 2026[14] - Liquidity at the end of Q3 2025 was $167 million, compared to $177 million in Q3 2024[18] - Net debt was $398 million, compared to $399 million in Q3 2024[18] Fiscal Year 2025 Guidance - Total revenue is projected to be between $540 million and $555 million[26] - Gross margin is expected to be between 40.5% and 41.5%[26] - Adjusted EBITDA is guided to be between $66 million and $73 million[26]

Financial Performance - Total revenue for Q3 2025 reached $278.6 million, an 11% increase year-over-year compared to $250.4 million in Q3 2024[31] - NUPLAZID net sales in Q3 2025 were $177.5 million, a 12% increase year-over-year from $159.2 million in Q3 2024[31] - DAYBUE net sales in Q3 2025 hit a record $101.1 million, an 11% increase year-over-year compared to $91.2 million in Q3 2024[31, 13] - The company's EPS (diluted) increased by 110% to $0.42 in Q3 2025, compared to $0.20 in Q3 2024[31] - The company updated its full-year 2025 revenue guidance to $1.07 to $1.095 billion[32] Commercial Updates - NUPLAZID referrals grew by 21% year-over-year[17] - New prescriptions for NUPLAZID increased by 23% year-over-year[19] - 74% of new prescriptions (NBRx) for DAYBUE came from community physicians in Q3[16, 15] - Over 1,006 patients have been treated with DAYBUE globally[14] Research and Development - A Phase 2 study of ACP-204 for Lewy Body Dementia Psychosis was initiated[10, 27] - A Phase 3 trial of trofinetide for Rett syndrome in Japan was initiated[10, 27]

Q3 2025 Financial Performance - Contribution ex-TAC reached $166.8 million, a 12% increase year-over-year[16] - CTV Contribution ex-TAC was $75.8 million, up 18% year-over-year[16] - DV+ Contribution ex-TAC was $90.9 million, a 7% increase year-over-year[16] - Net income was $20.1 million, or $0.13 per diluted share, compared to $5.2 million, or $0.04 per diluted share in Q3 2024[16] - Adjusted EBITDA was $57.2 million, a 13% increase year-over-year, with a 34% Adjusted EBITDA margin[16] - Non-GAAP earnings per share were $0.20, compared to $0.17 for Q3 2024[16] Q4 2025 Guidance - Total Contribution ex-TAC is projected to be between $191 million and $196 million, representing growth of 6% to 9%[19] - CTV Contribution ex-TAC is expected to be between $87 million and $89 million, representing growth of 12% to 14%[19] - DV+ Contribution ex-TAC is anticipated to be between $104 million and $107 million, representing growth of 2% to 5%[19] Full-Year Expectations - The company continues to expect total Contribution ex-TAC growth above 10%[22] - The company expects mid-teens percentage growth of Adjusted EBITDA[22]

Q3 2025 Performance - Total revenue reached $773 million, approaching the high end of guidance[6] - Adjusted EBITDA exceeded guidance, reaching $100 million[6] - Core advertising revenue increased by 7% year-over-year[9] Station Portfolio Optimization - 11 partner station acquisitions have closed as of November 5[12] - These acquisitions are expected to contribute at least $30 million in incremental annualized adjusted EBITDA[12] 2026 Political Revenue Outlook - The company anticipates exceeding $333 million in political revenue in 2026[17] Capital Structure - Total Sinclair Television Group (STG) debt at the end of 3Q25 was $4.1 billion[23] - Consolidated cash at the end of 3Q25 was $526 million ($122 million at SBG, $404 million at Ventures)[23] - On October 6, STG redeemed $89 million of Senior Unsecured Notes due 2027[23] Q4 2025 Guidance - Media revenue is projected to be in the range of $809 million to $845 million[33] - Core advertising is expected to be up over 10% at the midpoint of the range compared to 4Q24[37] - Distribution revenue is expected to be lower by 1% at the midpoint of the range compared to 4Q24[37] - Adjusted EBITDA is projected to be between $132 million and $154 million[37]

Third Quarter 2025 Performance - Production volume increased by 17% to 2.249 million short tons compared to 1.917 million short tons in Q3 2024[17] - Sales volume increased by 27% to a record 2.355 million short tons, including 378 thousand short tons from the Blue Creek mine[11, 17] - Average net selling price decreased by 21% to $135.87 per short ton from $171.92 per short ton in Q3 2024[17] - Revenue remained relatively flat at $328.6 million compared to $327.7 million in Q3 2024[17] - Net income decreased by 12% to $36.6 million from $41.8 million in Q3 2024[17] - Cash cost of sales decreased by 18% to $100.73 per short ton from $123.45 per short ton in Q3 2024[12, 17] Nine Months Ended September 30, 2025 Performance - Production volume increased by 11% to 6.811 million short tons compared to 6.140 million short tons in the same period of 2024[19, 21] - Sales volume increased by 11% to 6.746 million short tons compared to 6.088 million short tons in the same period of 2024[19, 21] - Average net selling price decreased by 33% to $133.92 per short ton from $198.48 per short ton in the same period of 2024[19, 21] - Revenue decreased by 25% to $926.1 million from $1.2278 billion in the same period of 2024[19, 21] - Net income decreased significantly by 86% to $34.0 million from $249.5 million in the same period of 2024[19, 21]

Information, statements and projections contained in these presentation slides and related conference call concerning Fortinet's business outlook, the fourth quarter and full year 2025 guidance, and future prospects and expectations are forward-looking statements that involve risks and uncertainties. These forward-looking statements include statements regarding any indications related to future growth and market share gains, our strategy going forward, and guidance and expectations around future financial r ...

McKesson Corporation Second Quarter Fiscal 2026 Earnings Call November 5, 2025 1 © 2021 McKesson Corporation. All rights reserved. Cautionary Statements Cautionary Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward- looking statements may be identified by their use of terminology such as "believes," "expects," "anticipates," "may," "will," "should," "seeks," "approxim ...

Financial Performance - MRD revenue reached $56.8 million, a 52% year-over-year increase[9] - Excluding milestones, MRD revenue grew by 55% year-over-year[9] - The company's sequencing gross margin was 66%, a 10 percentage point increase year-over-year[9] - The company has a strong cash position of approximately $217 million[9] - The company reduced cash burn by 51%, with 9-month cash burn of approximately $39 million compared to approximately $79 million in 2024[9] MRD Business - clonoSEQ US test volume increased by 38% year-over-year and 7% quarter-over-quarter[14] - clonoSEQ US ASPs (Average Selling Prices) increased by 28% year-over-year and 4% quarter-over-quarter[14] - The company has integrated 11 new EMR (Electronic Medical Records) sites since last quarter[16] Immune Medicine (IM) - Q3'25 revenue growth of 11% Y/Y including milestones (excluding milestones: +3% Y/Y)[19] - Recognized $6.5M in milestone revenue in Q3'25[19] - The company is on track to achieve its cash burn target, with revenue from pharma partnering continuing to fund R&D investment[24] FY 2025 Outlook - The company raised its MRD revenue guidance to between $202 million and $207 million, representing 39%-42% year-over-year growth[35] - The company lowered its OPEX (Operating Expenses) guidance to between $335 million and $340 million[33] - The company lowered its cash burn guidance to between $45 million and $50 million[34]

Q3 2025 Earnings November 5, 2025 Forward Looking Statements & Non-GAAP Financial Measures This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events or Lyft's future financial or operating performance. In some cases, you can identify forward looking statements because the ...